Online citations, reference lists, and bibliographies.
← Back to Search

New Guidelines To Evaluate The Response To Treatment In Solid Tumors

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther
Published 2000 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Anticancer agents go through a process by which their antitumor activity, on the basis of the amount of tumor shrinkage they could generate, has been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization (WHO) introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical cancer research joined together to undertake the review of these response evaluation criteria on the basis of their experience and knowledge. After several years of intensive discussions, new guidelines are ready and will replace the previous WHO criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors (Recist) Group and integrated into the present guidelines. This special article provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesion (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified. All other aspects of response evaluation have been discussed, reviewed, and amended whenever suitable.
This paper references

This paper is referenced by
Radiological assessment of tumour response to anti-cancer drugs: Time to reappraise
P. Nygren (2008)
Patient Tailored Resection Planning in Patients Undergoing Liver Surgery for Colorectal Liver Metastases; How and Why Should You Do It?
C. S. Kessel (2013)
Recent Developments in Kidney Cancer: Biomarkers, Mechanism, and Treatment
Qi Tang (2015)
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
Veridiana Pires de Camargo (2010)
Preoperative therapy for localized prostate cancer: a comprehensive overview.
Jensen Hu (2013)
A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Y. Fujisaka (2010)
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
J. Maurel (2009)
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
E. Kraut (2010)
MDCT Versus MRI Assessment of Tumor Response After Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
R. Kloeckner (2009)
A Web-Based Response-Assessment System for Development and Validation of Imaging Biomarkers in Oncology
H. Yang (2019)
Pathologic Assessment of Response to Chemotherapy in Colorectal Cancer Liver Metastases after Hepatic Resection: Which Method to Use?
K. Dede (2014)
Advancing Immune and Cell-Based Therapies Through Imaging
V. Ponomarev (2017)
Prognostic Impact of Paraneoplastic Cushing’s Syndrome in Small-Cell Lung Cancer
H. Nagy-Mignotte (2014)
Combination anastrozole and fulvestrant in metastatic breast cancer.
R. Mehta (2012)
Circulating Endothelial Cells and Microparticles as Prognostic Markers in Advanced Non-Small Cell Lung Cancer
T. Fleitas (2012)
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade
K. Tsai (2016)
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
P-E Heudel (2017)
Second-line systemic therapy for metastatic colorectal cancer.
S. Mocellin (2017)
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
X. Liu (2016)
Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
A. Stein (2012)
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
Thomas E. Hutson (2014)
Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules
S. Sciacchitano (2015)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy
S. Pignata (2011)
The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
Zixu Yuan (2013)
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
F. Nugent (2005)
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma1
C. Bazelaire (2005)
Challenges and Opportunities for In Vivo Imaging in Oncology
D. Sullivan (2002)
Complete Remission of Recurrent Gastrointestinal Stromal Tumors After Treatment with Imatinib: Report of a Case
M. Kobayashi (2006)
Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
C. Brogsitter (2005)
Integrado EM Medicina (2014)
Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)
P. Hesketh (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar